Erythropoietin and Engineered Innate Repair Activators
-
Last Update: 2021-02-28
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Erythropoietin (EPO) is a pleiotropic type I cytokine that has been identified as a major endogenous tissue protective molecule. In response to injury, EPO and a distinct receptor are expressed with a characteristic temporal and spatial expression pattern. Together, these serve to limit injury and to initiate repair. Administration of EPO in the setting of injury has been shownto be beneficial in a multitude of preclinical models. However, translation into the clinic has been hampered by EPO’s adverseeffects, including promotion of thrombosis. Recently, engineered molecules based on EPO’s structure–activity relationshipshave been developed that are devoid of hematopoietic effects. These compounds are promising candidates for treatment of awide variety of acute and chronic diseases.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
